


# Pocket Guide



<b>Introduction</b>	3
<b>Certificates of Attendance &amp; CME Accreditation</b>	4
<b>Conference Exhibitions &amp; Poster Sessions</b>	5
Commercial and Scientific Exhibitions	5
Poster Sessions	5
<b>ESWI Conference Refreshments &amp; Functions</b>	6
Coffee Breaks	6
Lunches	6
ESWI Welcome Dinner	7
ESWI Anniversary Dinner	7
<b>Email and Internet Service</b>	8
Access in Official Hotels	8
<b>ESWI Conference Transportation</b>	9
Departure Information	9
Airport Transfer	9
<b>Banking Information</b>	10
Banks	10
Lost or Stolen Bank Cards	11
<b>Conference Contact Information</b>	12
GCO – ESWI Conference Organisers	12
Conference Venue	13
Hotels	13
Hotel Floor Plans	14
<b>Programme Scientific Sessions</b>	18
<b>Programme Science in Practice</b>	27

## **Introduction**

Welcome to the Third European Influenza Conference in Vilamoura.

This pocket guide contains information that you may find useful during your stay and during your participation at the conference.

We wish you a productive meeting and a pleasant stay.

With kind regards,

The Organizing Committee

## **Certificates of Attendance & CME Accreditation**

Certificates of Attendance and CME Accreditation are available for collection in the registration area at the end of the conference. If you are departing early, please go the conference Information Desk for assistance.



## Conference Exhibitions & Poster Sessions

### Commercial and Scientific Exhibitions

The commercial exhibition is located in the Winter Garden on level 00, adjacent to the Gemini Room.

The scientific exhibition is located in the Aquarius room on level 0, adjacent to the Poster Display in the Blue Corner.

#### Exhibition Opening Hours:

Sunday 14 September 2008	12:00 - 17:00
--------------------------	---------------

Monday 15 September 2008	08:30 - 18:00
--------------------------	---------------

Tuesday 16 September 2008	08:30 - 18:00
---------------------------	---------------

Wednesday 17 September 2008	08:30 - 12:00
-----------------------------	---------------

### Poster Sessions

The ESWI Poster Sessions will be held in the Poster Display areas, in the Blue Corner on level 0 and the Winter Garden on level 00.

ESWI is pleased to offer you a selection of Port Wine and Soft Drinks during this time.

#### Poster Session Hours:

Monday 15 September 2008	17:00 - 18:00
--------------------------	---------------

Tuesday 16 September 2008	17:00 - 18:00
---------------------------	---------------

## **ESWI Conference Refreshments & Functions**

### **Coffee Breaks**

Refreshments will be served during morning and afternoon conference session breaks. The serving point is in the Commercial Exhibition (level 00).

#### **Coffee Break Hours:**

Monday 15 September 2008	10:00 - 10:30 & 15:00 - 15:30
Tuesday 16 September 2008	10:00 - 10:30 & 15:00 - 15:30
Wednesday 17 September 2008	10:00 - 10:30

### **Lunches**

ESWI is pleased to offer buffet lunches to all conference delegates on a complimentary basis. The primary serving point is in the Aries 2 restaurant with smaller ones being located in the adjoining Aries 1 and Orion restaurants. You are free to eat your lunch in the restaurants or outdoors on the terrace next to the hotel swimming pool.

#### **Lunch Hours:**

Monday 15 September 2008	12:00 - 13:30
Tuesday 16 September 2008	12:00 - 13:30
Wednesday 17 September 2008	13:00 - 14:30

# Pocket Guide

## **ESWI Welcome Dinner**

The ESWI Welcome Dinner will be held in the Nikki Beach Lakeside venue, which is located within the grounds of the Tivoli hotel.

Dress code is smart casual, but please wear comfortable flat-soled shoes as part of the venue has sand underfoot. You should wear your delegate name badge and bring the entrance ticket that was included in your registration pack.

### **ESWI Welcome Dinner Hours:**

Sunday 14 September 2008

20:30 - 22:30

---

## **ESWI Anniversary Dinner**

The ESWI Anniversary Dinner is the main evening function on the conference programme and will celebrate 15 years of ESWI. The dinner will be held in the grounds of the Tivoli hotel with the dress code being as per the Welcome Dinner. Please wear your name badge and bring your entrance ticket.

### **ESWI Anniversary Dinner Hours:**

Tuesday 16 September 2008

20:30 - 23:00

---

## **Email and Internet Service**

ESWI is pleased to provide all delegates with complimentary internet access during the conference. Internet access is in the form of WiFi broadband and hotspots have been set-up in the Fenix meeting room area, commercial exhibition and luncheon terrace areas. To access this service, please use the username and password provided in your registration pack.

### **Access in Official Hotels**

If you are staying in the Tivoli, there is cabled broadband in the bedrooms and you can use the same username and password as for the conference area.

If you are staying in the Vile Gale Ampalius or Vile Gale Marina, there is wireless broadband in the lobby area; please request your username and password from reception.

If you are staying in one of the other official hotels, there is wireless broadband in the lobby area and no username/password is required.

## **ESWI Conference Transportation**

### **Departure Information**

ESWI offers a complimentary transfer service to Faro International Airport on Wednesday 17 September. Should your return be on another day, a transfer can be arranged for you. Please go to the conference Information Desk in the registration area for more details and prices of this service.

### **Airport Transfer**

On the day of your departure, please meet your driver in the lobby of your hotel at the time indicated on your departure notice. If you have arranged to leave from the conference venue, please wait in the lobby of the Tivoli hotel.

## **Banking Information**

### **Banks**

There are two banks within easy walking distance of the Tivoli hotel. Both offer foreign currency exchange and have ATM machines.

#### **BANIF**

Avenida Tivoli - Condomínio Mourapraia Lote 2.7

Tel: +351 (0)289 381 210

#### **Caixa Geral De Depositos**

Avenida Tivoli, Lote 2 / 7A - Edifício Moura Praia, Bl. D Lojas 16 e 17

Tel: +351 (0)289 300 250

### **Typical banking hours**

Monday – Friday:

08:30-15:00

---

## Pocket Guide

### Lost or Stolen Bank Cards

Lost or stolen bank cards and credit cards should be reported to the Police Station closest to where the theft or loss occurred. The Police will provide a certificate for your issuing bank and your insurance company. It is called the *Auto de Denúncia de Furto*.

For all lost or stolen credit cards issued in Portugal, please contact the SIBS (Sociedade Interbancaria de Servicos):

SIBS Tel: +351 (0)808 201 251 or +351 (0)217 813 080

---

For all lost or stolen credit cards issued outside of Portugal, contact the Portuguese office of your card provider:

American Express	Tel: +351 (0)214 270 400
------------------	--------------------------

---

Mastercard	Tel: +351 (0)800 811 272
------------	--------------------------

---

Visa	Tel: +351 (0)800 811 107
------	--------------------------

---

## Conference Contact Information

### GCO – ESWI Conference Organisers

Our team is ready to assist you throughout the duration of the ESWI conference. The conference Information Desk is located in registration area on level 0.

#### Opening Hours:

Saturday 13 September 2008	14:00 – 18:00
Sunday 14 September 2008	09:00 - 20:00
Monday 15 September 2008	06:30 - 18:30
Tuesday 16 September 2008	06:30 - 18:30
Wednesday 17 September 2008	06:30 - 15:00

Out of office hours contact during conference  
(Sunday through Wednesday)

(+351) 96 219 25 91

(+351) 96 219 25 92

# Pocket Guide

## Conference Venue

Tivoli Marina Vilamoura Hotel  
8125-901 Vilamoura, Portugal  
Tel: +351 (0)289 303 303

## Hotels


Alfamar Beach	Tel: +351 (0)289 501 351
Dom Pedro Golf	Tel: +351 (0)289 300 700
Dom Pedro Marina	Tel: +351 (0)289 381 000
Hilton Vilamoura	Tel: +351 (0)289 304 000
Tivoli Marina Vilamoura	Tel: +351 (0)289 303 303
The Lake Resort	Tel: +351 (0)289 320 700
Vilamoura Beach	Tel: +351 (0)289 381 600
Vile Gale Ampalius	Tel: +351 (0)289 303 900
Vile Gale Marina	Tel: +351 (0)289 300 000
















**LEVEL 00**



# Pocket Guide

## LEVEL 0



Plenary/Scientific Sessions	FENIX	
Satellite Symposia	FENIX	
Break-out room 1	GEMINI	
Break-out room 2	NEPTUNO	
Overflow room	NEPTUNO	
Poster Presentations	BLUE CORNER	
	WINTER GARDEN	
Press Office	VEGA	
Hospitality Suites	HIDRA/DELFIN/TAURUS	
Speaker ready room	MEDUSA	
ESWI office	PEGASO	
GCO office	PEGASO	
Registration	LOBBY	
Lunch	ORION/ARIES	
Coffee Breaks		

EVIDENCE  
• BASED •  
VACCINE



PO Box 900, NL 1380 DA Weesp  
T +31 294 477 322  
E [influenza@solvay.com](mailto:influenza@solvay.com)  
W [www.solvay-influenza.com](http://www.solvay-influenza.com)

Solvay  
Biologicals



# Global Dedication to Influvaccination

Influvac® offers a global and reliable concept  
in influenza vaccination.

The subunit influenza vaccine is proven  
safe and effective for more than 25 years.

Influvac® is conveniently given  
with the easy-to-use DupharJect® syringe.

Influvac®: the simple solution  
for powerful protection.

*influvac*®

Power to protect

# Programme Scientific Sessions

## SUN 14 September 2008

13h00-14h30 SATELLITE SYMPOSIUM FENIX

– GSK Biologicals

15h00-16h30 SATELLITE SYMPOSIUM FENIX

– Solvay Biologicals

16h45-18h15 SATELLITE SYMPOSIUM FENIX

– Baxter

18h30-19h30 **OPENING OF THE CONFERENCE** FENIX

– keynote lecture by Dr R. Anderson, *Imperial College of London, UK*: Plagues and People: Planning for Pandemics

20h30-23h00 CONFERENCE WELCOME DINNER

## MON 15 September 2008

7h00-8h30 SATELLITE SYMPOSIUM FENIX

– Infectious Diseases Society of Finland, supported by MedImmune

8h45-10h00 **PLENARY 1** FENIX

- **PL01-1** keynote lecture by Dr P. Palese, *Mount Sinai School of Medicine, USA*: Genes contributing to the pathogenicity of pandemic influenza viruses
- **PL01-2** keynote lecture by Dr A. Monto, *University of Michigan, USA*: Prepandemic vaccines: yes or no?

10h00-10h30 COFFEE BREAK

10h30-12h00 **SESSION 1** SS01 NEPTUNO

### Virus host interaction/pathogenesis/transmission

**CHAIR:** Dr A. Garcia-Sastre, *Mount Sinai School of Medicine, USA*

**CO-CHAIR YS:** Dr G. Conenello, *Mount Sinai School of Medicine, USA*

#### DISCUSSANTS:

- **SS01-1** Dr A. Garcia-Sastre, *Mount Sinai School of Medicine, USA*: Interferon antagonist functions of the NS1 protein of influenza virus
- **SS01-2** Dr Y. Kawaoka, *University of Wisconsin School of Veterinary Medicine, USA*
- **SS01-3** Dr T. Tumpey, *Centers for Disease Control, USA*: Mutations that affect the transmissibility of influenza A viruses

- **SS01-4** Dr. T. Kuiken, *Erasmus MC*: Pathology of influenza in humans revisited
- **SS01-5** Dr G. Conenello, *Mount Sinai School of Medicine, USA*: Increased Pathogenesis by influenza A virus expressing a PB1-F2 protein with the N66S mutation: role of CD8+ and CD4+T-cells

## SESSION 2 SS02

FENIX

### Clinical impact & diagnostics approaches

**CHAIR:** Dr F. Hayden, *World Health Organisation, Switzerland*

**CO-CHAIR YS:** Dr J. Kovar, *University College London, UK*

**DISCUSSANTS:**

- **SS02-1** Dr T. Heikkinen, *University of Turku, Finland*: Disease burden and diagnosis of influenza in children
- **SS02-2** Dr K. Nicholson, *University of Leicester, UK*: Burden of influenza and other respiratory viruses in a University Hospital setting at the extremes of life
- **SS02-3** Dr M. De Jong, *The Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam*: Human H5N1 disease: pathogenesis and treatment
- **SS02-4** Dr M. Rothberg, *Tufts University, USA*: Mortality Benefits of Statins for Pneumonia when Influenza is Circulating

12h00-13h30 LUNCH

## SATELLITE SYMPOSIUM

FENIX

- European Vaccine Manufacturers

13h30-15h00 SESSION 3 SS03

NEPTUNO

### Virus structure & replication

**CHAIR:** Dr R. Lamb, *Howard Hughes Medical Institute, USA*

**CO-CHAIR YS:** Dr E. De Wit, *Department of Virology, Erasmus MC, The Netherlands*

**DISCUSSANTS:**

- **SS03-1** Dr R. Krug, *University of Texas, USA*: Multiple Functions of the NS1 Protein of Influenza A Viruses
- **SS03-2** Dr R. Lamb, *Howard Hughes Medical Institute, USA*: Influenza Virus Budding
- **SS03-3** Dr N. Naffakh, *Institut Pasteur, France*: The influenza virus RNA polymerase: a key determinant for viral host-range and pathogenicity, a target for antiviral strategies
- **SS03-4** Dr E. Carnero, *Mount Sinai School of Medicine, USA*: Nucleotides outside the predicted packaging sequences of the HA segment of influenza A virus influence the incorporation of this segment into virions

## Vaccines: current and novel approaches

**CHAIR:** Dr A. Osterhaus, *Erasmus MC, The Netherlands*

**CO-CHAIR YS:** Dr J. Steel, *Mount Sinai School Of Medicine, New York, USA*

**DISCUSSANTS:**

- **SS04-1** Dr M. Tashiro, *National Institute of Infectious Diseases, Japan*: The TLR3 agonist, PolyI:PolyC12U, added to Influenza vaccines as a nasal adjuvant induces a wide spectrum cross-protection against different subtypes including highly pathogenic H5N1 avian influenza virus
- **SS04-2** Dr W. Fiers, *Ghent University, Belgium*: A Universal Human Influenza A Vaccine
- **SS04-3** Dr T. Vesikari, *University of Tampere Medical School, Finland*: MF59™ Adjuvanted Influenza Vaccine (Fluad®) in Children: Safety and Immunogenicity Following a Second Year Seasonal Vaccination
- **SS04-4** Dr J. Kreijtz, *Erasmus MC Department of Virology, The Netherlands*: Recombinant modified vaccinia virus Ankara expressing HA confers protection against homologous and heterologous H5N1 influenza virus infections in macaques

15h00-15h30 COFFEE BREAK

15h30-17h00 SESSION 5 SS05

FENIX

## Late Breakers

**CHAIR:** Dr J. Katz, *Centers for Disease Control and Prevention, USA*

**CO-CHAIR YS:** Dr A. Lowen, *Mount Sinai School of Medicine, USA*

**DISCUSSANTS:**

- Dr Boettcher, *Institute of Virology, Philipps University Marburg, Germany*: Membrane-associated human airway trypsin-like protease (HAT) cleaves the influenza virus hemagglutinin at the cell surface

SESSION 6 SS06

NEPTUNO

## How to evaluate vaccine effectiveness?

**CHAIR:** Dr A. Monto, *University of Michigan, USA*

**DISCUSSANTS (PANEL DISCUSSION):**

- **SS06-1** Dr L. Simonsen, *National Institutes of Health, USA*: Influenza Vaccination and Mortality Benefits: New Insights, New Opportunities
- **SS06-2** Dr K. Nichol, *Minneapolis VA Medical Center, USA*: Challenges in evaluating influenza effectiveness

- **SS06-3** Dr E. Hak, *University Medical Center Utrecht, The Netherlands*: Impact of influenza vaccination on mortality risk among the elderly: methodological inquiry
- **SS06-4** The Chochrane Collaboration (*to be confirmed*)

**17h00-18h00** POSTER SESSION

**BLUE CORNER  
WINTER GARDEN**

**18h00-19h30** SATELLITE SYMPOSIUM

**FENIX**

– F. Hoffmann-La Roche

## TUE 16 September 2008

**7h00-8h30** SATELLITE SYMPOSIUM

**FENIX**

– Sanofi Pasteur MSD

**8h45-10h00** PLENARY 2

**FENIX**

**CHAIR:** Dr C. Russell, *University of Cambridge, UK*

**CO-CHAIR:** Dr C. Hannoun, *ESWI Young Scientist Fund*

**LECTURES BY ESWI YOUNG SCIENTISTS AWARD WINNERS**

- **PL02-1** Dr C. Russell, *University of Cambridge, UK*: The Global Circulation of Seasonal Influenza A (H3N2) Viruses
- **PL02-2** Dr A. Lowen, *Mount Sinai School of Medicine, USA*: Influenza virus transmission: studies in the guinea pig model
- **PL02-3** Dr J. Schneider, *Robert Koch Institute, Germany*: The nonstructural NS1 protein of influenza B virus interacts with nuclear speckle domains
- **PL02-4** Dr E. Hutchinson, *University of Cambridge, UK*: Genetic analysis of cis-acting RNA sequences in influenza A
- **PL02-5** Dr K. Grebe, *NIH, USA*: The Sympathetic Nervous System Modulates Anti-Influenza CD8+ T cell Responses in vivo
- **PL02-6** Dr J. McAuley, *St Jude Children's Research Hospital, USA*: The 1918 Influenza A Virus PB1-F2 Protein Contributes to the Immunopathogenesis of Viral and Secondary Bacterial Pneumonia

**10h00-10h30** COFFEE BREAK

## Antivirals and resistance

**CHAIR:** Dr R. Krug, *University of Texas, USA*

**CO-CHAIR YS:** Dr M. Rameix-Welti, *Institut Pasteur, France*

**DISCUSSANTS:**

- **SS07-1** Dr W. DeGrado, *Department of Biochemistry and Biophysics, School of Medicine, University of Pennsylvania, USA:* How recently published structure of the M2 ion channel protein provides insights for developing new antivirals against this protein
- **SS07-2** Dr A. Hay, *National Institute of Medical Research, UK:* The Structural Basis of Neuraminidase Inhibitor Resistance
- **SS07-3** Dr M. Zambon, *Health Protection Agency, UK:* Oseltamivir Resistant Influenza A H1N1 Viruses
- **SS07-4** Dr M. Rameix-Welti, *Institut Pasteur, France:* Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir
- **SS07-5** Dr O. Ferraris, *CNRS, France:* Multiple detection of influenza A/H3 viruses lacking the Na gene segment

## SESSION 8

 SS08

## Genetic and antigenetic evolution

**CHAIR:** Dr N. Cox, *Centers for Disease Control and Prevention, USA*

**CO-CHAIR YS:** Dr R. Garten, *Influenza Division, Centers for disease control and prevention, USA*

**DISCUSSANTS:**

- **SS08-1** Dr A. Klimov, *Centers for Disease Control and Prevention, USA:* Evolution of Influenza Viruses and Vaccine Strain Selection Process
- **SS08-2** Dr B. Koel, *Department of Virology, Erasmus MC, The Netherlands:* Mapping the molecular determinants of antigenic evolution of the influenza A (H3N2) virus
- **SS08-3** Dr N. Lewis, *University of Cambridge, UK:* The antigenic and genetic evolution of equine influenza virus (h3n8) from 1976 to 2007
- **SS08-4** Dr J. Bollback, *University of Edinburgh, UK:* Reassortment and recombination in influenza
- **SS08-5** Dr E. Fournier, *CNRS, France:* Influenza A packaging control by RNA/RNA interactions: identification of critical domains also controlling genetic reassortment

- **LUSS-1** Dr C. Schmaltz, *European Commission, Research Directorate General: How far is it to Brussels? - Your voice in EU research funding for influenza*
- **LUSS-2** Dr J. Serratos, *European Food Safety Authority (EFSA), Animal Health and Welfare (AHAW): High Pathogen Avian Influenza: EFSA's evaluation of risks in Animal Health*

13h30-15h00

SESSION 9 SS09

FENIX

## Animal flu-ecology

**CHAIR:** Dr R. Fouchier, *Erasmus MC, The Netherlands*

**CO-CHAIR YS:** Dr N. Lewis, *University of Cambridge, UK*

**DISCUSSANTS:**

- **SS09-1** Dr D. Suarez, *USA Department of Agriculture, USA: Avian Influenza in the Live Bird Markets in the U.S.*
- **SS09-2** Dr R. Webster, *St. Jude Children's Research Hospital, USA: The role of migratory birds in the origin and perpetuation of influenza viruses*
- **SS09-3** Dr V. Munster, *Department of Virology, Erasmus MC, The Netherlands: Avian influenza virus; virus and bird ecology*
- **SS09-4** Dr I. Brown, *Veterinary Laboratory Agency, UK: Multiple incursions of H5N1 highly pathogenic avian influenza virus in to Europe*
- **SS09-5** Dr K. Van Reeth, *Ghent University, Belgium : Immunity to H1N1 swine influenza virus can partially protect pigs against a low pathogenic H5N1 avian influenza virus*

SESSION 10 SS10

NEPTUNO

## Mathematical modeling

**CHAIR:** Dr D. Smith, *University of Cambridge, UK*

**CO-CHAIR YS:** Dr W. Alonso, *Fogarty International Center- National Institutes of Health, Florianopolis, Brazil*

**DISCUSSANTS:**

- **SS10-1** Dr P. Thomas, *St. Jude Children's Research Hospital, USA: CD8 T cell epitope recognition: broad detection through a narrow window*
- **SS10-2** Dr I. Longini, *Fred Hutchinson Cancer Research Center, USA: Mathematical Modeling of Pandemic Influenza Containment and Control*
- **SS10-3** Dr S. Cauchemez, *MRC Centre for Outbreak Analysis and Modelling, Department of Infectious Diseases Epidemiology, Imperial College London, UK: Estimating the impact of school closure on influenza transmission from Sentinel data*

- **SS10-4** Dr C. Viboud, *Fogarty International Center, National Institutes of Health, Bethesda, USA*: Extreme risk of influenza death among young adults: A comparative modeling study of the 1918-20 pandemic in 13 countries
- **SS10-5** Dr B. Cowling, *University of Hong Kong, Hong Kong*: Estimating the serial interval of influenza from natural infections in households

**15h00-15h30** COFFEE BREAK

**15h30-17h00** **SESSION 11** SS11

**NEPTUNO**

## Immunology

**CHAIR:** Dr J. Yewdell, *NIAID, NIH, USA*

**CO-CHAIR YS:** Dr A. Wahl, *University of Oklahoma, USA*

**DISCUSSANTS:**

- **SS11-1** Dr G. Air, *University of Oklahoma Health Sciences Center, USA*: Antibody quality versus quantity
- **SS11-2** Dr H. Lu, *Influenza Division, NCIIRD, CDC, USA*: Influenza A H1N1 neuraminidase antibodies fail to provide cross-protection against lethal challenge with a highly pathogenic avian influenza A H5N1 infection in mice
- **SS11-3** Dr H. Golding, *CBER, FDA, USA*: Analysis of Antibody Repertoires in H5N1 Infected and Vaccinated Individuals using Influenza Whole Genome Phage Display Libraries
- **SS11-4** Dr G. Rimmelzwaan, *Erasmus MC, The Netherlands*: Influenza virus CTL epitopes, remarkably conserved and remarkably variable
- **SS11-5** Dr J. Yewdell, *NIAID, NIH, USA*: tRNA Misacylation: A novel Innate Immune Response to Viruses” – CTLs, Misacylation, and Super-coding

**SESSION 12** SS12

**FENIX**

## Vaccine evaluation

**CHAIR:** Dr J. Wood, *National Institute for Biological Standards and Control, UK*

**CO-CHAIR YS:** Dr J. Kwong, *Institute For Clinical Evaluative Sciences, Toronto, Canada*

**DISCUSSANTS:**

- **SS12-1** Dr J. Wood, *National Institute for Biological Standards and Control, UK*: New challenges for influenza vaccine development
- **SS12-2** Dr D. Skowronski, *BC Center for Disease Control, Canada*: Component-specific efficacy of trivalent influenza vaccine: sentinel surveillance to detect virus variation and impact on protection

- **SS12-3** Dr D. Shay, *CDC, USA*: Multi-state Case-control Study of the Effectiveness of Influenza Vaccine in Preventing Laboratory-confirmed Influenza Hospitalizations among Children Aged 6-23 months during the 2005-06 and 2006-07 Seasons
- **SS12-4** Dr J.C. Kwong, *Institute for Clinical Evaluative Sciences, Canada*: The effect of universal influenza immunization on mortality and health care use
- **SS12-5** Dr N. Sugaya, *Keiyu Hospital, Japan*: Mass Vaccination of Schoolchildren and Influenza Outbreaks in a School

**17h00-18h00** POSTER SESSION

**BLUE CORNER  
WINTER GARDEN**

**18h00-19h30** SATELLITE SYMPOSIUM

**FENIX**

- Novartis

**20h30-23h00** ESWI ANNIVERSARY DINNER

## WED 17 September 2008

7h00-8h30 SATELLITE SYMPOSIUM

– Sanofi Pasteur

8h45-10h00 **PLENARY 3**

**FENIX**

- **PL03-1** Keynote lecture by Dr M. Peiris, *University of Hong Kong, Hong Kong: Avian Influenza from the South East Asian Perspective*
- **PL03-2** Keynote lecture by Dr D. Swayne, *Southeast Poultry Research Laboratory, USDA/Agricultural Research Service*  
*Veterinary influenza vaccines: Strategies and Challenges to the Development and Application of Avian Influenza Vaccines in Birds*

10h00-10h30 COFFEE BREAK

10h30-12h00 **PLENARY 4**

**FENIX**

### Pandemic preparedness

**CHAIR:** Dr K. Fukuda, *World Health Organisation, Switzerland*

**CO-CHAIR:** Dr K. Ekdahl, *ECDC, Sweden*

#### DISCUSSANTS:

- **PL04-1** Dr J. Katz, *Influenza Division, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA: Assessing the Pandemic Risk of Avian Influenza Viruses*
- **PL04-2** Dr N. Ferguson, *University of London, UK: Predicting the impact of layered interventions*
- **PL04-3** Dr J. Van-Tam, *University of Nottingham, UK*
- **PL04-4** Dr J. Watkins, *University of Wales, UK: Pandemic Planning at a Sub-National Level*

12h00-13h00 **CLOSING SESSION**

**FENIX**

- Keynote lecture by Dr A. Osterhaus, *Erasmus MC, The Netherlands*
- Awards to young scientists

13h00-14h30 LUNCH

# Programme Science in Practice

## SUN 14 September 2008

13h00-14h30 SATELLITE SYMPOSIUM FENIX

– GSK Biologicals

15h00-16h30 SATELLITE SYMPOSIUM FENIX

– Solvay Biologicals

16h45-18h15 SATELLITE SYMPOSIUM FENIX

– Baxter

18h30-19h30 OPENING OF THE CONFERENCE FENIX

– keynote lecture by Dr R. Anderson, *Imperial College of London, UK: Plagues and People: Planning for Pandemics*

20h30-23h00 CONFERENCE WELCOME DINNER

## MON 15 September 2008

7h00-8h30 SATELLITE SYMPOSIUM FENIX

– Infectious Diseases Society of Finland, supported by MedImmune

8h45-10h00 PLENARY 1 FENIX

- **PL01-1** keynote lecture by Dr P. Palese, *Mount Sinai School of Medicine, USA: Genes contributing to the pathogenicity of pandemic influenza viruses*
- **PL01-2** keynote lecture by Dr A. Monto, *University of Michigan, USA: Prepandemic vaccines: yes or no?*

10h00-10h30 COFFEE BREAK

10h30-12h00 SESSION 1 SIP01 GEMINI

### Increasing the overall epidemic vaccination coverage

CHAIR:

– Dr A. Monto, *University of Michigan, USA*

DISCUSSANTS:

– **SIP01-1** Dr D. Fedson, *France: Increasing the overall epidemic vaccination coverage: the macroepidemiology of influenza vaccination*

- **SIP01-2** Dr. T. Szucs, *Institute of Social and Preventive Medicine, University of Zurich, Switzerland*: Influenza vaccination coverage rates in four European countries during winter of 2007/08
- **SIP01-3** Dr K. Nichol, *Minneapolis VA Medical Center, USA*: Maximizing seasonal influenza vaccination coverage

**12h00-13h30** LUNCH

SATELLITE SYMPOSIUM

FENIX

- European Vaccine Manufacturers

**13h30-15h00** **SESSION 2** SIP02

GEMINI

## Seasonal vaccination of health care workers

CHAIR:

- Dr T. van Essen, *University Medical Center Utrecht, The Netherlands*

DISCUSSANTS:

- **SIP02-1** Dr R. Jordan, *University of Birmingham, UK*: Effectiveness and cost-effectiveness of vaccinating healthcare workers against influenza, and strategies to improve uptake
- **SIP02-2** Dr H. Van Delden, *University Medical Center Utrecht, The Netherlands*: Ethics of mandatory vaccination against influenza for health care workers
- **SIP02-3** Dr D. Walter, *Robert Koch Institute, Germany*: National influenza immunization campaign – focus on health care workers

**15h00-15h30** COFFEE BREAK

**15h30-17h00** **SESSION 3** SIP03

GEMINI

## Epidemic and pandemic use of antivirals

CHAIR:

- Dr F. Hayden, *World Health Organisation, Switzerland*

DISCUSSANTS:

- **SIP03-1** Dr N. Ferguson, *University of London, UK*: Antiviral use in a pandemic: predicting impact and the risk of resistance
- **SIP03-2** Dr J. Van-Tam, *University of Nottingham, UK*
- **SIP03-3** Dr F. Hayden, *World Health Organisation, Switzerland*: Antivirals for Seasonal, A(H5N1), and Pandemic Influenza: Efficacy, Resistance, and New Agents

**17h00-18h00** POSTER SESSION

BLUE CORNER  
WINTER GARDEN

**18h00-19h30** SATELLITE SYMPOSIUM

FENIX

- F. Hoffmann-La Roche

## TUE 16 September 2008

7h00-8h30 SATELLITE SYMPOSIUM

FENIX

– Sanofi Pasteur MSD

8h45-10h00 PLENARY 2

FENIX

CHAIR:

– Dr C. Russell, *University of Cambridge, UK*

CO-CHAIR:

– Dr C. Hannoun, *ESWI Young Scientist Fund*

LECTURES BY ESWI YOUNG SCIENTISTS AWARD WINNERS

– **PL02-1** Dr C. Russell, *University of Cambridge, UK*: The Global Circulation of Seasonal Influenza A (H3N2) Viruses

– **PL02-2** Dr A. Lowen, *Mount Sinai School of Medicine, USA*: Influenza virus transmission: studies in the guinea pig model

– **PL02-3** Dr J. Schneider, *Robert Koch Institute, Germany*: The nonstructural NS1 protein of influenza B virus interacts with nuclear speckle domains

– **PL02-4** Dr E. Hutchinson, *University of Cambridge, UK*: Genetic analysis of cis-acting RNA sequences in influenza A

– **PL02-5** Dr K. Grebe, *NIH, USA*: The Sympathetic Nervous System Modulates Anti-Influenza CD8+ T cell Responses in vivo

– **PL02-6** Dr J. McAuley, *St Jude Children's Research Hospital, USA*: The 1918 Influenza A Virus PB1-F2 Protein Contributes to the Immunopathogenesis of Viral and Secondary Bacterial Pneumonia

10h00-10h30 COFFEE BREAK

10h30-12h00 SESSION 4 SIP04

GEMINI

### Prepandemic and pandemic vaccination

CHAIR:

– Dr D. Smith, *University of Cambridge, UK*

DISCUSSANTS (PANEL DISCUSSION):

– **SIP04-1** Dr B. Schwartz, *National Vaccine Program Office, USA*: Prioritizing pandemic influenza vaccination: public values and public policy

– **SIP04-2** Dr I. Longini, *Fred Hutchinson Cancer Research Center, USA*: Strategies for Containing or Slowing the Spread of Pandemic Influenza

– **SIP04-3** Dr A. Osterhaus, *Erasmus MC, The Netherlands*: Pandemic vaccination: constraining a moving target

12h00-13h30 LUNCH

**LUNCH SESSION****FENIX**

- **LUSS-1** Dr C. Schmaltz, *European Commission, Research Directorate General*: How far is it to Brussels? - Your voice in EU research funding for influenza
- **LUSS-2** Dr J. Serratosa, *European Food Safety Authority (EFSA), Animal Health and Welfare (AHAW)*: High Pathogen Avian Influenza: EFSA's evaluation of risks in Animal Health

**13h30-15h00** **SESSION 5** SIP05**GEMINI****Social distancing during a pandemic****CHAIR:** Dr N. Ferguson, *University of London, UK***DISCUSSANTS:**

- **SIP05-1** Dr J. Edmunds, *Health Protection Agency, UK*
- **SIP05-2** Dr M. Cetron, *Centers for Disease Control and Prevention, USA*: US community mitigation planning
- **SIP05-3** Dr B. Schwartz, *National Vaccine Program Office, USA*: Mitigating secondary consequences of non-pharmaceutical interventions during an influenza pandemic

**15h00-15h30** **COFFEE BREAK****15h30-17h00** **SESSION 6** SIP06**GEMINI****Equitable use of intervention strategies in a pandemic****CHAIR:** Dr K. Fukuda, *World Health Organisation, Switzerland***DISCUSSANTS:**

- **SIP06-1** Dr A. Nicoll, *ECDC, Sweden*: Where are we now and what needs to be done – pandemic countermeasure in Europe
- **SIP06-2** Dr S. Jadhav, *Serum Institute of India, India*: Pandemic flu vaccine preparedness : Developing Countries Vaccine Manufacturers' perspective
- **SIP06-3** Dr L. Hessel, *International Federation of Pharmaceutical Manufacturers & Associations, France*: The industry contribution to the equitable availability of vaccines in a pandemic situation
- **SIP06-4** Dr D. Reddy, *Hoffmann-La Roche, Switzerland*: Access to antiviral stockpiles for pandemic use – an industry perspective

**17h00-18h00** **POSTER SESSION****BLUE CORNER  
WINTER GARDEN****18h00-19h30** **SATELLITE SYMPOSIUM****FENIX**

– Novartis

**20h30-23h00** **ESWI ANNIVERSARY DINNER**

## WED 17 September 2008

7h00-8h30 SATELLITE SYMPOSIUM

FENIX

– Sanofi Pasteur

8h45-10h00 PLENARY 3

FENIX

- **PL03-1** Keynote lecture by Dr M. Peiris, *University of Hong Kong, Hong Kong: Avian Influenza from the South East Asian Perspective*
- **PL03-2** Keynote lecture by Dr D. Swayne, *Southeast Poultry Research Laboratory, USDA/Agricultural Research Service*  
*Veterinary influenza vaccines: Strategies and Challenges to the Development and Application of Avian Influenza Vaccines in Birds*

10h00-10h30 COFFEE BREAK

10h30-12h00 PLENARY 4

FENIX

### Pandemic preparedness

**CHAIR:** Dr K. Fukuda, *World Health Organisation, Switzerland*

**CO-CHAIR:** Dr K. Ekdahl, *ECDC, Sweden*

#### DISCUSSANTS:

- **PL04-1** Dr J. Katz, *Influenza Division, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA: Assessing the Pandemic Risk of Avian Influenza Viruses*
- **PL04-2** Dr N. Ferguson, *University of London, UK: Predicting the impact of layered interventions*
- **PL04-3** Dr J. Van-Tam, *University of Nottingham, UK*
- **PL04-4** Dr J. Watkins, *University of Wales, UK: Pandemic Planning at a Sub-National Level*

12h00-13h00 CLOSING SESSION

FENIX

- Keynote lecture by Dr A. Osterhaus, *Erasmus MC, The Netherlands*
- Awards to young scientists

13h00-14h30 LUNCH

MAIN SPONSORS



SPONSORS

